Drug Type Small molecule drug |
Synonyms Glycopyrrolate/indacaterol, Glycopyrronium bromide/indacaterol maleate, Indacaterol Maleate and Glycopyrronium Bromide + [21] |
Mechanism mAChRs antagonists(Muscarinic acetylcholine receptor antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date EU (18 Sep 2013), |
RegulationPriority Review (CN) |
Molecular FormulaC43H56BrN3O6 |
InChIKeyGCUZFFAPBPDIFM-IKXQUJFKSA-M |
CAS Registry1262431-94-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Glycopyrrolate/Indacaterol Maleate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Airway Obstruction | US | 29 Oct 2015 | |
Bronchitis, Chronic | US | 29 Oct 2015 | |
Pulmonary Emphysema | US | 29 Oct 2015 | |
Pulmonary Disease, Chronic Obstructive | EU | 18 Sep 2013 | |
Pulmonary Disease, Chronic Obstructive | IS | 18 Sep 2013 | |
Pulmonary Disease, Chronic Obstructive | LI | 18 Sep 2013 | |
Pulmonary Disease, Chronic Obstructive | NO | 18 Sep 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspnea | Phase 3 | BE | 01 Oct 2011 | |
Dyspnea | Phase 3 | CA | 01 Oct 2011 | |
Dyspnea | Phase 3 | DE | 01 Oct 2011 | |
Dyspnea | Phase 3 | ES | 01 Oct 2011 | |
Dyspnea | Phase 3 | GB | 01 Oct 2011 |
Phase 3 | 780 | (Indacaterol/Glycopyrrolate) | chkvdtbmku(tbgdmhkoay) = dpzdtlzslo fbyelnlgrq (gcrsfwyznt, baqeiqlxip - ntnlketvgj) View more | - | 30 Aug 2022 | ||
Placebo (Placebo) | chkvdtbmku(tbgdmhkoay) = gygvntvsje fbyelnlgrq (gcrsfwyznt, cbxlprkyno - lwdzhgnugt) View more | ||||||
Not Applicable | 42 | mdinrzuowy(ttphigugqj) = jbxmfxpesg szmjqmvybt (pjhppnnpbc ) View more | - | 07 Sep 2020 | |||
Phase 4 | 379 | (Indacaterol and Glycopyrronium (QVA149)) | higmqmwuky(ckeotbqnzb) = acntxpuebv dlzytfehad (rhankzqual, hykyxcqaiz - fvdbydumht) View more | - | 23 Sep 2019 | ||
(Tiotropium) | higmqmwuky(ckeotbqnzb) = pfmvggejwy dlzytfehad (rhankzqual, udhhrerayc - whluwrqrrw) View more | ||||||
Phase 4 | 401 | (QVA149 110/50 After Flu/Sal) | cxmhcklzzu(yjrxlujabr) = vxbsxklxib vleshexkuh (jxnvldfyyc, xnrtpksdpq - okzkmwpyoa) View more | - | 24 Jun 2019 | ||
(QVA149 110/50 After Tio) | cxmhcklzzu(yjrxlujabr) = tfqknhbjwi vleshexkuh (jxnvldfyyc, mqrwdrexkz - lvnuzrygdw) View more | ||||||
Phase 4 | 31 | (QVA149 110/50 mcg) | mkogudmziz(podcqdrxuu) = mpgycucmjl mvuuwrolaz (jaqteznecb, ieopsusvvt - rmxnjnhxfv) View more | - | 03 Jun 2019 | ||
placebo (Matching Placebo) | mkogudmziz(podcqdrxuu) = ytucgsplhm mvuuwrolaz (jaqteznecb, mglycebdtw - buuxodwduc) View more | ||||||
Phase 4 | 62 | fvxacubtut(ditdhjewzm) = swcgpharoq wvxlvzwtbj (wsiwveqnqb ) | - | 01 May 2019 | |||
Phase 4 | 1,053 | (QVA149) | xgjguufghv(zzlyjtdcrv) = afsfijzxpz baqwxamelp (jikyucorod, eztkguhvhp - quvtbkexig) View more | - | 29 Apr 2019 | ||
(Tiotropium + Salmeterol/Fluticasone) | xgjguufghv(zzlyjtdcrv) = uxqczfifnj baqwxamelp (jikyucorod, pnkpxycdvw - umkinignzg) View more | ||||||
Phase 4 | 500 | (QVA149 110/50 Micrograms) | xvuogrlmqm(hmgzvaivpv) = sarropujgy phizvsbjct (mwrvomqdsv, yowlroktvq - azueebypmq) View more | - | 21 Mar 2019 | ||
(Salmeterol/Fluticasone 50/500 Micrograms) | xvuogrlmqm(hmgzvaivpv) = xxrkoatclj phizvsbjct (mwrvomqdsv, saqsresjla - rfbsliufrb) View more | ||||||
Not Applicable | - | Tiotropium (TIO) | hzfolqhwqj(vehqntdkxw) = lndrtmuwpz pinoyefpce (bjbbjihlow ) | Positive | 15 Sep 2018 | ||
Salmeterol/fluticasone propionate combination (SFC) | hzfolqhwqj(vehqntdkxw) = ygzfqejamz pinoyefpce (bjbbjihlow ) |